^
Association details:
Evidence:
Evidence Level:
Resistant: C3 โ€“ Early Trials
New
Source:
Title:

Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)

Excerpt:
Two VEGFR3 missense polymorphisms, VEGFR3 rs307821 (R1324L) and VEGFR3 rs307826 (T494A), showed a trend toward reduced PFS in GEP NETs (HR: 12.3; 95% CI 1.09โ€“139ยท2; P = 0.042 and HR: 6.9; 95% CI 0.96โ€“49.9; P = 0.055...Pazopanib showed clinical activity in patients with advanced NETs regardless of previous treatments.
DOI:
10.1093/annonc/mdv252
Trial ID: